10th June 2015, Newcastle upon Tyne, England. Pioneering medical diagnostics developer QuantuMDx announces that it is exploring licensing opportunities for its rapid DNA extraction kit Q-PREP at BIO in Philadelphia, June 15th to 18th.
Q-PREP is a next generation DNA extraction technology set to dramatically shorten and simplify the molecular work flow for PCR, sequencing and other molecular processes. The technology is presently being deployed in next-generation spin columns to access the predicted $1bn (2018) market for DNA spin-columns.
CSO Jonathan O’Halloran explains “Next generation spin columns using Q-PREP technology are simple to use; just add a lysate and spin once for very high yield and high-quality DNA. This allows laboratories to optimize their time and resources by creating a more efficient workflow. Q-PREP is the first significant disruptive technology in the field for decades and we are excited to find the right partner to help commercialise it.”
Announced to coincide with the company’s attendance at BIO 2015 COO Sam Whitehouse said “We are looking forward to discussing licensing opportunities for Q-PREP, as well as providing updates on the development of our handheld molecular diagnostic device Q-POC™.”
COO Dr Sam Whitehouse and Business Development Manager Dr Jonathan Peat will attend BIO 2015 as part of the UK Pavilion (Stand 1127), run by UK Trade and Investment (UKTI) in partnership with the UK BioIndustry Association and the Mayor of London Export Group.
If you are interested in meeting Dr Whitehouse or Dr Peat to discuss Q-PREP licensing opportunities or Q-POC™ development whilst you are at BIO International Convention 2015 please contact Dr Peat on jonathan.peat@quantumdx.com.
The convention will be held at the Pennsylvania Convention Centre, Philadelphia on 15th - 18th June 2015.
--- END ---
Press Enquiries
Lucy Harvey
Business Development and Marketing Officer, QuantuMDx Group Ltd
lucy.harvey@quantumdx.com
0870 803 1234
About QuantuMDx Group
QuantuMDx Group is a multinational medical device developer headquartered in the United Kingdom, with subsidiary operations in the United States and Singapore. Expected for commercialisation in 2016, Q-POC will empower overburdened healthcare systems worldwide with gold standard molecular diagnostics at a fraction of the cost of traditional testing.
The company’s flagship product is Q-POC™, a handheld DNA analyser that will diagnose disease in 15 minutes for a few pounds at the patient’s side. Q-POC’s superior multiplexing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent ‘right first time prescribing’. QuantuMDx was co-founded by CEO Elaine Warburton OBE, inventor and CSO Jonathan O’Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee. QuantuMDx has received grants from the UK and EU governments, and partnered with FIND in 2014.
Help employers find you! Check out all the jobs and post your resume.
